查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433619

寡核苷酸合成的全球市场规模、份额和趋势分析报告：按产品/服务、应用、地区和细分市场预测（2024-2030）

Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report By Product & Service (Oligonucleotides, Equipment/Synthesizer), By Application (PCR Primers, PCR Assays & Panels), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 135 Pages | 商品交期: 2-10个工作天内

价格

寡核苷酸合成市场成长与趋势：

预计2030年，全球寡核苷酸合成市场规模将达85.3亿美元，2024年至2030年复合年增长率为13.21%。临床试验中强大的寡核苷酸疗法管道、基因编辑技术的进步以及生物技术公司不断增加的研发支出是推动市场成长的一些关键因素。

参与的寡核苷酸疗法正处于后期临床试验中，预计将在预测期内核准和商业化。公司正在增加投资以开发基于寡核苷酸的疗法。 2023年10月，GSK plc和Arrowhead Pharmaceuticals与强生旗下杨森製药公司（Janssen）达成协议，获得JNJ-3989的全球独家开发和商业化权利。宣布签署协议，将该公司转让给GSK 。杨森最初于 2018 年从 Arrowhead 引入了 JNJ-3989（以前称为 ARO-HBV）。成熟製药公司的类似倡议预计将在预测期内推动市场成长。

政府机构，例如负责实验室的医疗补助和医疗保险服务中心、负责行销的联邦贸易委员会以及负责套件和资讯的FDA，确保基因组学和基因检测的安全、适当和准确，并在成功中发挥着关键作用基因体学。美国国立卫生研究院和威康信託基金等国际资助机构也正在资助基因研究，预计将重振已开发经济体和新兴经济体的基因组研究。

2021 年 5 月，英国政府宣布为基因组学研究和资料驱动计画提供 4,340 万美元（3,700 万倡议）资助，并于 2019 年 9 月启动了英国功能基因组计画和英国基因组实施计画。 Genomics UK 策略将在 Genomics England计划的帮助下实施，该计画将获得 1,990 万美元（1,700 万英镑）来研究新生儿定序的潜在价值。

寡核苷酸合成市场报告亮点：

  • 按产品/服务划分，服务业在市场中占据主导地位，2023 年份额将超过 37.0%。
  • 按应用分，PCR引子细分市场在2023年占据最大市场占有率。它们在放大特定 DNA 或 RNA 序列方面发挥着至关重要的作用，使其成为该市场的重要组成部分。
  • 由于主要企业的增加、各种应用中对合成 DNA 和 RNA 序列的需求不断增加以及有利的监管环境等因素，北美主导了市场。
  • 2023年5月，金斯瑞将扩建位于中国江苏省镇江市的生命科学设施，为研发和临床前应用提供快速、高纯度的寡核苷酸和胜肽合成服务。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章寡核苷酸合成市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 业务分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影响分析

第四章寡核苷酸合成市场：产品与服务的估算与趋势分析

  • 产品和服务的市场占有率（2023/2030）
  • 市场规模、预测、趋势分析（2018-2030）

第五章寡核苷酸合成市场：应用预估及趋势分析

  • 应用市场占有率（2023/2030）
  • 市场规模、预测、趋势分析（2018-2030）

第六章寡核苷酸合成市场：区域估计与趋势分析

  • 区域市场占有率分析（2023/2030）
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争形势

  • 公司/竞争对手分类
  • 策略规划
  • 企业市场分析（2023）
  • 公司简介/名单
    • Thermo Fisher Scientific, Inc.
    • Merck KGaA
    • Danaher Corporation
    • Dharmacon Inc.
    • Agilent Technologies
    • Bio-synthesis
    • Kaneka Eurogentec SA
    • LGC Biosearch Technologies
    • Biolegio
    • Twist Bioscience
Product Code: GVR-2-68038-593-9

Oligonucleotide Synthesis Market Growth & Trends:

The global oligonucleotide synthesis market size is projected to reach USD 8.53 billion by 2030, registering a CAGR of 13.21% from 2024 to 2030, according to a new report by Grand View Research, Inc. The strong pipeline of oligonucleotide therapeutics in clinical trials, advancements in gene editing technologies, and increasing R&D spending by biotechnology companies are some of the major factors driving the market growth.

Oligonucleotide therapeutics participants are present in the late stages of clinical trials and are expected to be approved & commercialized over the forecast period. Companies have increased investments to develop oligonucleotide-based therapeutics. In October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen initially in-licensed JNJ-3989 (previously ARO-HBV) from Arrowhead in 2018. Similar initiatives by well-established pharmaceutical companies are anticipated to drive market growth over the forecast period.

Government bodies, such as the Centers for Medicaid & Medicare Services for labs, the Federal Trade Commission for marketing, and the FDA for kits & information, have played a key role in the success of genomics, as they have been involved in monitoring the safe, appropriate, and accurate application of genomics & genetic tests. International funding bodies, such as NIH and Wellcome Trust, are engaged in providing funds for genetic studies, which is expected to fuel genomic studies in developed and emerging economies.

In May 2021, the UK government announced a funding of USD 43.4 million (GBP 37 million) for genomics research and data-driven initiatives, delivered via the UK Functional Genomics Initiative and Genome UK Implementation Plan, which was started in September 2019. The Genome UK strategy will be implemented with the help of the Genomics England project, which will receive USD 19.9 million (GBP 17 million) to investigate the potential value of newborn sequencing.

Oligonucleotide Synthesis Market Report Highlights:

  • Based on product & services, the service segment dominated the market with more than 37.0% share in 2023 owing to the growing demand for specialized services and increasing number of demands for outsourcing services
  • Based on application, the PCR primers segment held the largest market share in 2023. Their crucial role in amplifying specific DNA or RNA sequences makes them an essential component of the market
  • North America dominated the market owing to factors such as increasing the presence of key players, increasing demand for synthetic DNA & RNA sequences in various applications, and favorable regulatory scenario
  • In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product & service
    • 1.2.2. Application
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Landscape Insights

Chapter 3. Oligonucleotide Synthesis Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Strong pipeline of oligonucleotide therapeutics in clinical trials
      • 3.2.1.2. Changing regulatory environments for genetic research and its applications in healthcare
      • 3.2.1.3. High R&D spending of pharmaceutical & biotechnology companies
      • 3.2.1.4. Increased public-private spending on genomics
      • 3.2.1.5. Technological advancements in gene editing technologies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Need for advanced oligo synthesis solutions
      • 3.2.2.2. High cost associated with genomics research
      • 3.2.2.3. Lack of skilled professionals and research support in undeveloped countries
  • 3.3. Business Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Oligonucleotide Synthesis Market: Product & Service Estimates & Trend Analysis

  • 4.1. Product & Service Market Share, 2023 & 2030
  • 4.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 4.2.1. Oligonucleotides
      • 4.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.2. DNA
      • 4.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.2.2. Column-based
      • 4.2.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.2.3. Array-based
      • 4.2.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3. RNA
      • 4.2.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.2. By Technology
      • 4.2.1.3.2.1. Column-based
      • 4.2.1.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.2.2. Array-based
      • 4.2.1.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.3. By Type
      • 4.2.1.3.3.1. Short RNA Oligos (<65 nt)
      • 4.2.1.3.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.3.2. Long RNA Oligos (>65 nt)
      • 4.2.1.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.1.3.3.3. CRISPR (sgRNA)
      • 4.2.1.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.2.2. Equipment/Synthesizer
      • 4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.2.3. Reagents
      • 4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.2.4. Services
      • 4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2. DNA
      • 4.2.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2. Custom oligo synthesis services
      • 4.2.4.2.2.1. 25 nmol
      • 4.2.4.2.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2.2. 50 nmol
      • 4.2.4.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2.3. 200 nmol
      • 4.2.4.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2.4. 1000 nmol
      • 4.2.4.2.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.2.5. 10000 nmol
      • 4.2.4.2.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.3. Modification services
      • 4.2.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.2.4. Purification services
      • 4.2.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3. RNA
      • 4.2.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.2. Custom oligo synthesis services
      • 4.2.4.3.2.1. 25 nmol
      • 4.2.4.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.2.2. 100 nmol
      • 4.2.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.2.3. 1000 nmol
      • 4.2.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.2.4. 10000 nmol
      • 4.2.4.3.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.3. Modification services
      • 4.2.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.2.4.3.4. Purification services
      • 4.2.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Oligonucleotide Synthesis Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 5.2.1. PCR primers
      • 5.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.1.2. Academic research institutes
      • 5.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.1.2.2. Diagnostic laboratories
      • 5.2.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.1.2.3. Pharmaceutical - biotechnology companies
      • 5.2.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.2. PCR assays and panels
      • 5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.2.2. Academic research institutes
      • 5.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.2.2.2. Diagnostic laboratories
      • 5.2.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.2.2.3. Pharmaceutical - biotechnology companies
      • 5.2.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.3. Sequencing
      • 5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.3.2. Academic research institutes
      • 5.2.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.3.2.2. Diagnostic laboratories
      • 5.2.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.3.2.3. Pharmaceutical - biotechnology companies
      • 5.2.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.4. DNA microarrays
      • 5.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.4.2. Academic research institutes
      • 5.2.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.4.2.2. Diagnostic laboratories
      • 5.2.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.4.2.3. Pharmaceutical - biotechnology companies
      • 5.2.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.5. Fluorescence in situ hybridization (FISH)
      • 5.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.5.2. Academic research institutes
      • 5.2.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.5.2.2. Diagnostic laboratories
      • 5.2.5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.5.2.3. Pharmaceutical - biotechnology companies
      • 5.2.5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.6. Antisense oligonucleotides
      • 5.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.6.2. Academic research institutes
      • 5.2.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.6.2.2. Diagnostic laboratories
      • 5.2.6.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.2.6.2.3. Pharmaceutical - biotechnology companies
      • 5.2.6.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.7. Other applications
      • 5.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Oligonucleotide Synthesis Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. North America
    • 6.2.1. U.S.
      • 6.2.1.1. Key country dynamics
      • 6.2.1.2. Regulatory framework
      • 6.2.1.3. Competitive scenario
      • 6.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.2.2. Canada
      • 6.2.2.1. Key country dynamics
      • 6.2.2.2. Regulatory framework
      • 6.2.2.3. Competitive scenario
      • 6.2.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. UK
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Germany
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. France
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.4. Italy
      • 6.3.4.1. Key country dynamics
      • 6.3.4.2. Regulatory framework
      • 6.3.4.3. Competitive scenario
      • 6.3.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.5. Spain
      • 6.3.5.1. Key country dynamics
      • 6.3.5.2. Regulatory framework
      • 6.3.5.3. Competitive scenario
      • 6.3.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.6. Norway
      • 6.3.6.1. Key country dynamics
      • 6.3.6.2. Regulatory framework
      • 6.3.6.3. Competitive scenario
      • 6.3.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.7. Sweden
      • 6.3.7.1. Key country dynamics
      • 6.3.7.2. Regulatory framework
      • 6.3.7.3. Competitive scenario
      • 6.3.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.8. Denmark
      • 6.3.8.1. Key country dynamics
      • 6.3.8.2. Regulatory framework
      • 6.3.8.3. Competitive scenario
      • 6.3.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Japan
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. India
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Australia
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Thailand
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Brazil
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Mexico
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. South Africa
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. UAE
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Kuwait
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company/Competition Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position Analysis, 2023
  • 7.4. Company Profiles/Listing
    • 7.4.1. Thermo Fisher Scientific, Inc.
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Merck KGaA
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Danaher Corporation
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Dharmacon Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Agilent Technologies
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Bio-synthesis
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Kaneka Eurogentec S.A
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. LGC Biosearch Technologies
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Biolegio
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Twist Bioscience
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global oligonucleotide synthesis market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 4 North America oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 5 North America oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 7 U.S. oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 8 Canada oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 9 Canada oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 10 Europe oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 11 Europe oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 12 Europe oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 13 Germany oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 14 Germany oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 15 UK oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 16 UK oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 17 France oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 18 France oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 19 Italy oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 20 Italy oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 21 Spain oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 22 Spain oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 23 Denmark oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 24 Denmark oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 25 Sweden oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 26 Sweden oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 27 Norway oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 28 Norway oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 32 China oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 33 China oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 34 Japan oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 35 Japan oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 36 India oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 37 India oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 38 South Korea oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 39 South Korea oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 40 Australia oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 41 Australia oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 42 Thailand oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 43 Thailand oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 44 Latin America oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 45 Latin America oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 46 Latin America oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 47 Brazil oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 48 Brazil oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 49 Mexico oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 50 Mexico oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 51 Argentina oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 52 Argentina oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 53 MEA oligonucleotide synthesis market, by country, 2018 - 2030 (USD Million)
  • Table 54 MEA oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 55 MEA oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 56 South Africa oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 57 South Africa oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 60 UAE oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 61 UAE oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 62 Kuwait oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 63 Kuwait oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Oligonucleotide synthesis market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Synthetic biology market value, 2023 (USD billion)
  • Fig. 16 Market trends & outlook
  • Fig. 17 Top investors in drug R&D as a percentage of net sales (2019)
  • Fig. 18 PESTEL analysis
  • Fig. 19 Porter's five forces analysis
  • Fig. 20 Oligonucleotide synthesis market: Product & service outlook & key takeaways
  • Fig. 21 Oligonucleotide synthesis market: Product & service movement analysis
  • Fig. 22 Oligonucleotides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 DNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Column-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Array-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 RNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Column-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Array-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Short RNA oligos (<65 nt) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Long RNA oligos (>65 nt) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 CRISPR (sgRNA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Equipment/synthesizer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Reagents market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 DNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Custom oligo synthesis services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 25 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 50 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 200 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 1,000 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 10,000 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Modification services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Purification services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 RNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Custom oligo synthesis services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 25 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 100 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 1,000 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 10,000 nmol market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Modification services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Purification services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Oligonucleotide synthesis market: Application outlook & key takeaways
  • Fig. 53 Oligonucleotide synthesis market: Application movement analysis
  • Fig. 54 PCR primers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 PCR assays and panels market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Sequencing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 DNA microarrays market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Fluorescence In Situ Hybridization (FISH) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Antisense oligonucleotides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Regional marketplace outlook, 2023 & 2030, (USD Million)
  • Fig. 62 Regional marketplace: Key takeaways
  • Fig. 63 North America oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 U.S. key country dynamics
  • Fig. 65 U.S. oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Canada key country dynamics
  • Fig. 67 Canada oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Europe oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 UK key country dynamics
  • Fig. 70 UK oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Germany key country dynamics
  • Fig. 72 Germany oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 France key country dynamics
  • Fig. 74 France oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Spain key country dynamics
  • Fig. 76 Spain oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Italy key country dynamics
  • Fig. 78 Italy oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Denmark key country dynamics
  • Fig. 80 Denmark oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Sweden key country dynamics
  • Fig. 82 Sweden oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Norway key country dynamics
  • Fig. 84 Norway oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Asia Pacific oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Japan key country dynamics
  • Fig. 87 Japan oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 China key country dynamics
  • Fig. 89 China oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 India key country dynamics
  • Fig. 91 India oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Australia Key country dynamics
  • Fig. 93 Australia oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Thailand key country dynamics
  • Fig. 95 Thailand oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 South Korea key country dynamics
  • Fig. 97 South Korea oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Latin America oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Brazil key country dynamics
  • Fig. 100 Brazil oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Mexico key country dynamics
  • Fig. 102 Mexico oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Argentina key country dynamics
  • Fig. 104 Argentina oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 MEA oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 South Africa key country dynamics
  • Fig. 107 South Africa oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Saudi Arabia key country dynamics
  • Fig. 109 Saudi Arabia oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 UAE key country dynamics
  • Fig. 111 UAE oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Kuwait key country dynamics
  • Fig. 113 Kuwait oligonucleotide synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 114 Market participant categorization
  • Fig. 115 Global oligonucleotide synthesis market position analysis, 2023
  • Fig. 116 Strategic framework